They already have a drug approved in 2012 generating about $7mil in yearly revs. They are currently due to release full results for their PH2 trial for CF drug by the end of Q1. They released preliminary results last week and they look ok. Current price $.42 Target price - short term $.60, long term $1 by eoy

Chromadex sells nutritional additives and nutrition consulting. Currently they have a few products they sell and market. Their current product with the highest sales is Nicotinamide riboside. Per SEC filings, last year CDXC had $22mil in revs. In the first 9 months of 2016 they had $21mil in revs. Last year they ended the fiscal year with a share price around $4.20/share. Currently priced at $3.65 that leaves the company valued at about 30% less than 2016 based solely off of revenues which will be approximately 25% MORE than fiscal 2015. Since their uplifting in 2009 the company has been uptrending in price. Recently they have had their first coverage by an analyst with a $6 PT. This week they have a presentation at the ICR conference at 11:30AM wednesday where they will be trying to gather Investor Money and interest for filing a IND with the FDA for using their best compound for clinical trials. With a 25 mil share float, this could be a mover on volume. I believe this is more of a long hold though for 2017. I believe their revs are steadily increasing and they will get Private investor funding for their ph1 trials. They are already working with Johnson and Johnson since 2015 with their products.

I believe their $6 PT will be obtainable in 2017.

Ipo'd earlier in 2016 at $6 and went to $9's only to fade back to its current $1.60 range. There was a recent pop last week to $1.96 and it may be the oversold buying or short covering for 2016. Either way this looks like a good entry point for a long 2016 hold through PH2 trial testing. If the FDA grants the IND application it might see a huge spike in January. Very low short float at 1.4% but also 5mil share float. E warned thoug, they might put an offering if the price jumps above $3/ share since they didn't raise much cash in their ipo.

Link for good TheStreet write up.

FDA announced last week they don't believe their 900 patient ph3 study effectively showed the safety profile of their post surgical implantable pain relief drug. It showed promising ph3 results in trials. Currently there is only one other comparable drug on the market and its a $200MIL/yr in sales drug. They have enough cash to get them through mid 2017 (30MIL) If management can convince the FDA, they might be able to have a chance. They MUST raise cash ASAP if they want to get this drug to market with another ph3 trial.

IMO I would wait to invest in this co until management figures out some direction. There may be a pop after a few days but shorts will be in control. link to news

Positive P2 HBV vaccine Positive Hep B trial close to 52W lows

Very low on cash Just approved another 1mil shares to issue

Link for a quick review

PT $3 by EOY

I am testing waters for a weekly stock picking contest. Please respond to this thread if interested. Once I get at least 5 participants I will make a google sheets document for the pics. Any thoughts or suggestions please post.

The rules would be as followed:

1- Must provide 2 stock picks

2- Both picks must be Biotech or Healthcare related stocks

3- Must trade on USA or Canadian exchanges

4- Must provide at least one sentence explanation for each pick you made

5- OTC stocks permitted with mods approval

Current ph3 cervical cancer trials interim results due in a few months, this could easily double on good news. I was prior shorted 32% before the Amgen deal was announced. Also news on their listeria vaccine developments can help nudge up the price. Last conference slideshow

So they had some issues with their trials earlier this year and had to halt the trial. Stock tanked and didn't recover. They have over $2 / share in cash and currently trading at $1.20's after the jump today on news that a Dione has firm is buying 60% of them and merging. New company will have current TKAI owners only holding 40% of the company.

Either way this looks fresh for a short squeeze.

After running out of money from poor data ph1 and ph2 diabetes trials lexicon brought in a new CEO, did a reverse split, piledrived investors with equity offerings, then started another ph2 trial in collaboration for T1 diabetes. So far the trial looks positive, after years of the same drug in the same trial showing even to placebo or not much better. news on recent trial Lexicon has some cash, but I believe after years of poor results for their drugs, if they continue higher, this will ultimately fail a PH3 trial. I expect the stock price to be In the $30-50 range by then setting up a nice potential short for trial failure to sub $10 ($6-7.50)

I have followed the stock and company for 6 years. It's not much different than others.

Just look at the chart, it's not pretty. But is there any potential for Concordia for 2017? It's looking bright after 3 weeks as the new CEO has started looking into what can be done to stop the bleeding of cash. They do have $400mil currently and it "will allow them to meet their current financial obligations" for the near future. They had $320 mil in sales last q but way more losses thanks to the buyout of another company earlier this year and the incurred expenses from that. I believe if we can see the light by march 2017 (2016 FY earnings) that this will be an easy multi bagger by eoy 2017. Then again they have boat loads of debt and there might be another's option of taking the company private and destroying shareholder equity. Latest pr from new CEO on operations

The LABU (Biotech Bull 3X ETF) is down 15% on the week due to uncertainty with Trumps Health Care bill. Voting on the bill was postponed indefinitely today. As a result LABU which was up over 3% at one point fall down to -1% on the day. Before the delay was announced, the chairman of the House Freedom Caucus (a group of conservative lawmakers who have opposed the bill) said that “no deal” had been reached yet after a meeting at the White House today.

It seems like there is a good chance that when voting does actually happen LABU could drop even farther. That might make it pretty cheap. If Trump continues to push to make drug approval quicker, simpler and cheaper I wouldn’t be shocked if it bounced back up to over $50 by year’s end.

https://compliantcloud.com/my-cloud-service-provider-is-iso-certified-isnt-that-enough/

In this video, I talk about the latest news in the biotech sector with details on my DCF model for Amarin and their fish oil pill, vascepa. I also talk about the limb-girdle data from Sarepta.

$SNMX

This company isn't such a biotech but more of a chemical company that makes food additives. Semonyx currently has contracts with PepsiCo and sells lots of product to them, mainly alternative sweeteners , for their pop and beverages. There were talks of new contracts with Coke but they haven't been finalized. That could easily push the price of this low cap to its analyst targets above $3.

This year they are on track for $21-23 million in sales.

They are finalizing their restructuring this quarter for earnings. It should help overall with net profits.

Price target is $2 by summer and $2.40 by EOY. Very conservative considering the PT of analyst

Just a heads up their internal review shows their stem cell therapy for spinal cord injuries was safe to use on Ph1/2 trials and are looking to continue trials with higher dosing than 20mil cells.

Company recently received coverage from Laidlaw and a $12 PT as well from HC Wainwright.

Small share float of 8% with 48mil total shares.

Estimated $.73/share in cash or about $33mil so an offering won't be around the corner for a bit.

Looking at short term $5 but rough waters ahead and may range from $3-6.

I'll just keep it simple here.

PFUDA date set for May 7 Their lead drug THX-001 has been developed for women with VAG pain who normally take Progesterone. Its a common side effect of menopause in older women to have vag pain. This drug showed at full dose of 1mg a 300% decrease over placebo in vag pain and had 0 (yes that's zero) major effects like placebo did. There were typical pain or discomfort issues reported. Even at half dose .5mg, it showed a 125% decrease over placebo. They even ran the trial at .25 and .1 just to make the FDA happy.

Currently at $4.80 this had a huge drop from $9 when the FDA released a document on their NDA that said some "details" were not ok. They did not say what details and management still has no clue what these Details are.

There has been some heavy options trading on this the past month. It looks like there was a lot of calls sold for premium and then closed out after the drop for may Expiration. Today there has been some HEAVY put buying for may $5 expiration.

There is a huge 12k position at $7.50 may expiration calls, so this looks like investors are expecting a FDA approval.

I am looking for a $8 target price which I believe will be obtainable with FDA approval. There is speculation the FDA is looking for warning labels for the minor side effects which might delay the NDA and send this to $2.50 level.